EP2844288A4 - Protéines de liaison à chaînes légères composées - Google Patents

Protéines de liaison à chaînes légères composées

Info

Publication number: EP2844288A4
Authority: EP; European Patent Office
Prior art keywords: light chains; link proteins; compound; chains compound; proteins
Prior art date: 2012-05-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP13784481.7A

Other languages

German (de)

English (en)

Other versions

EP2844288A2 (fr

EP2844288B1 (fr

Inventor

Michael Hunter

Ronald Swanson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Biotech Inc

Original Assignee

Janssen Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-02

Filing date

2013-04-30

Publication date

2016-02-24

2013-04-30 Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc

2015-03-11 Publication of EP2844288A2 publication Critical patent/EP2844288A2/fr

2016-02-24 Publication of EP2844288A4 publication Critical patent/EP2844288A4/fr

2021-04-21 Application granted granted Critical

2021-04-21 Publication of EP2844288B1 publication Critical patent/EP2844288B1/fr

Status Active legal-status Critical Current

2033-04-30 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP13784481.7A 2012-05-02 2013-04-30 Protéines de liaison à chaînes légères composées Active EP2844288B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261641339P	2012-05-02	2012-05-02
PCT/US2013/038858 WO2013166011A2 (fr)	2012-05-02	2013-04-30	Protéines de liaison à chaînes légères composées

Publications (3)

Publication Number	Publication Date
EP2844288A2 EP2844288A2 (fr)	2015-03-11
EP2844288A4 true EP2844288A4 (fr)	2016-02-24
EP2844288B1 EP2844288B1 (fr)	2021-04-21

Family

ID=49512682

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP13784481.7A Active EP2844288B1 (fr)	2012-05-02	2013-04-30	Protéines de liaison à chaînes légères composées

Country Status (8)

Country	Link
US (1)	US9062120B2 (fr)
EP (1)	EP2844288B1 (fr)
JP (1)	JP6410711B2 (fr)
CA (1)	CA2871909C (fr)
DK (1)	DK2844288T3 (fr)
ES (1)	ES2869890T3 (fr)
IL (1)	IL235291B (fr)
WO (1)	WO2013166011A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160175458A1 (en)	2014-12-19	2016-06-23	Alkermes, Inc.	Single chain fc fusion proteins
EP3474884A4 (fr)	2016-06-22	2020-08-19	Alkermes, Inc.	Compositions et méthodes permettant de moduler les propriétés immunostimulantes et anti-inflammatoires de l'il-10
TWI874341B (zh)	2018-12-18	2025-03-01	美商健生生物科技公司	產生異二聚體抗體之方法
SI4065585T1 (sl)	2019-11-25	2025-11-28	Alkermes, Inc.	Substituirane makrociklične spojine ter z njimi povezani postopki zdravljenja
JP7784039B2 (ja)	2020-03-31	2025-12-11	公立大学法人大阪	多重特異性抗体及びその製造方法
US11760747B2 (en)	2020-12-21	2023-09-19	Alkermes, Inc.	Substituted piperidino compounds and related methods of treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010112194A1 (fr) *	2009-04-02	2010-10-07	F. Hoffmann-La Roche Ag	Polypeptides se liant à un antigène et anticorps multispécifiques les renfermant
WO2010115553A1 (fr) *	2009-04-07	2010-10-14	Roche Glycart Ag	Anticorps anti-erbb-2/anti-c-met bispécifiques

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5169939A (en)	1985-05-21	1992-12-08	Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College	Chimeric antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1994012520A1 (fr)	1992-11-20	1994-06-09	Enzon, Inc.	Segment de liaison pour polypeptides fusionnes lies
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
US7527787B2 (en) *	2005-10-19	2009-05-05	Ibc Pharmaceuticals, Inc.	Multivalent immunoglobulin-based bioactive assemblies
EP1293514B1 (fr)	2001-09-14	2006-11-29	Affimed Therapeutics AG	Multimères d'anticorps Fv monocaténaires en tandem
CA2599265A1 (fr) *	2005-02-28	2006-09-08	Centocor, Inc.	Compositions de liaison proteinique de forme heterodimerique
TWI323734B (en)	2005-08-19	2010-04-21	Abbott Lab	Dual variable domain immunoglobulin and uses thereof
WO2007085814A1 (fr)	2006-01-24	2007-08-02	Domantis Limited	Protéines de fusion contenant des jonctions naturelles
US20070274985A1 (en)	2006-05-26	2007-11-29	Stefan Dubel	Antibody
EP2626371A1 (fr)	2007-07-31	2013-08-14	MedImmune, LLC	Protéines de liaison d'épitope multispécifique et leurs utilisations
US8242247B2 (en)	2007-12-21	2012-08-14	Hoffmann-La Roche Inc.	Bivalent, bispecific antibodies
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
US8227577B2 (en)	2007-12-21	2012-07-24	Hoffman-La Roche Inc.	Bivalent, bispecific antibodies
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
TW201138821A (en) *	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
WO2012051111A2 (fr)	2010-10-13	2012-04-19	Janssen Biotech, Inc.	Anticorps contre l'oncostatine m humaine et procédés d'utilisation
KR101886983B1 (ko)	2011-08-23	2018-08-08	로슈 글리카트 아게	2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
JP5925893B2 (ja)	2011-08-23	2016-05-25	ロシュグリクアートアーゲー	二重特異性抗原結合分子

2013
- 2013-03-12 US US13/794,887 patent/US9062120B2/en active Active
- 2013-04-30 WO PCT/US2013/038858 patent/WO2013166011A2/fr not_active Ceased
- 2013-04-30 ES ES13784481T patent/ES2869890T3/es active Active
- 2013-04-30 DK DK13784481.7T patent/DK2844288T3/da active
- 2013-04-30 JP JP2015510383A patent/JP6410711B2/ja active Active
- 2013-04-30 EP EP13784481.7A patent/EP2844288B1/fr active Active
- 2013-04-30 CA CA2871909A patent/CA2871909C/fr active Active
2014
- 2014-10-23 IL IL235291A patent/IL235291B/en active IP Right Grant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010112194A1 (fr) *	2009-04-02	2010-10-07	F. Hoffmann-La Roche Ag	Polypeptides se liant à un antigène et anticorps multispécifiques les renfermant
WO2010115553A1 (fr) *	2009-04-07	2010-10-14	Roche Glycart Ag	Anticorps anti-erbb-2/anti-c-met bispécifiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ROLAND KONTERMANN: "Dual targeting strategies with bispecific antibodies", MABS, LANDES BIOSCIENCE, US, vol. 4, no. 2, 1 March 2012 (2012-03-01), pages 182 - 197, XP009160769, ISSN: 1942-0870, DOI: 10.4161/MABS.4.2.19000 *
See also references of WO2013166011A2 *
W. SCHAEFER ET AL: "Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 27, 20 June 2011 (2011-06-20), US, pages 11187 - 11192, XP055241993, ISSN: 0027-8424, DOI: 10.1073/pnas.1019002108 *

Also Published As

Publication number	Publication date
CA2871909C (fr)	2021-04-20
US9062120B2 (en)	2015-06-23
DK2844288T3 (da)	2021-06-14
EP2844288A2 (fr)	2015-03-11
JP6410711B2 (ja)	2018-10-24
EP2844288B1 (fr)	2021-04-21
WO2013166011A2 (fr)	2013-11-07
CA2871909A1 (fr)	2013-11-07
US20130295084A1 (en)	2013-11-07
IL235291A0 (en)	2014-12-31
WO2013166011A9 (fr)	2014-01-09
WO2013166011A3 (fr)	2014-02-27
IL235291B (en)	2021-06-30
ES2869890T3 (es)	2021-10-26
JP2015517467A (ja)	2015-06-22

Publication	Publication Date	Title
EP2807754A4 (fr)	2016-01-06	Transmission multipoint coordonnée à liaison ascendante
EP2702928A4 (fr)	2015-09-02	Source lumineuse
BR112013023808A2 (pt)	2016-12-13	montagem de ligação
LT3865581T (lt)	2024-10-25	Pelės su humanizuota universalia lengvąja grandine
EP2882996A4 (fr)	2016-04-13	Luminaires à diffraction
EP2914901A4 (fr)	2016-06-08	Système d'éclairage
EP2979389A4 (fr)	2016-11-16	Établissement d'une liaison optique
BR302012004582S1 (pt)	2014-05-27	Configuracao aplicada em lampada de led
DE112013001416A5 (de)	2014-12-04	Flächenlichtquelle
EP2880474A4 (fr)	2016-03-23	Nanocouche influençant la lumière
EP2676760A4 (fr)	2014-08-06	Structure de liaison de panneaux
EP2867105A4 (fr)	2016-04-13	Maillon de chenille
DK2823691T3 (da)	2019-07-15	Led-lyskilde
EP2719911A4 (fr)	2016-07-27	Joint homocinétique fixe
EP2937624A4 (fr)	2016-06-22	Lampe à del
EP2793918A4 (fr)	2015-11-18	Peptides de liaison à hdc-sign
EP2907602A4 (fr)	2016-06-01	Composition de liaison
BR302012005409S1 (pt)	2013-10-15	Configuração aplicada em luminária.
PT2814965T (pt)	2018-05-23	Proteínas pesticidas manipuladas
EP2844288A4 (fr)	2016-02-24	Protéines de liaison à chaînes légères composées
EP2792896A4 (fr)	2016-08-03	Joint homocinétique fixe
PT3260761T (pt)	2021-07-02	Matriz de luz multicolorida
BR302012004583S1 (pt)	2014-05-27	Configuracao aplicada em lampada de led
PT2842395T (pt)	2018-05-22	Redes de iluminação distribuída
EP2865686A4 (fr)	2016-04-13	Peptide de liaison à edfr

Legal Events

Date	Code	Title	Description
2015-02-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2015-03-11	17P	Request for examination filed	Effective date: 20141202
2015-03-11	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2015-03-11	AX	Request for extension of the european patent	Extension state: BA ME
2015-08-05	DAX	Request for extension of the european patent (deleted)
2016-02-24	A4	Supplementary search report drawn up and despatched	Effective date: 20160125
2016-02-24	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/46 20060101ALI20160119BHEP Ipc: C07K 16/24 20060101ALI20160119BHEP Ipc: A61K 39/395 20060101AFI20160119BHEP
2017-08-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2017-09-20	17Q	First examination report despatched	Effective date: 20170817
2020-11-05	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2020-11-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2020-12-02	INTG	Intention to grant announced	Effective date: 20201106
2021-03-17	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2021-03-19	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2021-03-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2021-04-21	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-04-21	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2021-04-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE V, CH
2021-05-12	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602013077039 Country of ref document: DE Ref country code: IE Ref legal event code: FG4D
2021-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1383937 Country of ref document: AT Kind code of ref document: T Effective date: 20210515
2021-06-01	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2021-06-02	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2021-06-14	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20210608
2021-08-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2021-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1383937 Country of ref document: AT Kind code of ref document: T Effective date: 20210421
2021-10-26	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2869890 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211026
2021-10-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210721
2021-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210821 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210722 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210721 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210823
2021-12-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210430
2022-01-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602013077039 Country of ref document: DE
2022-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421
2022-02-25	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2022-02-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2022-03-30	26N	No opposition filed	Effective date: 20220124
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210821 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421
2023-04-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20230310 Year of fee payment: 11
2023-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130430
2023-05-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20230310 Year of fee payment: 11 Ref country code: BE Payment date: 20230315 Year of fee payment: 11
2023-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421
2023-06-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20230314 Year of fee payment: 11
2023-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20230414 Year of fee payment: 11 Ref country code: CH Payment date: 20230502 Year of fee payment: 11
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421
2024-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421
2024-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210421
2024-11-25	REG	Reference to a national code	Ref country code: DK Ref legal event code: EBP Effective date: 20240430
2024-11-29	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2024-12-04	REG	Reference to a national code	Ref country code: NL Ref legal event code: MM Effective date: 20240501
2024-12-27	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20240430
2025-01-02	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2025-01-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240430 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240501
2025-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240501 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240430 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240430
2025-04-15	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240430
2025-04-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240430
2025-04-25	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20250310 Year of fee payment: 13
2025-04-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20250320 Year of fee payment: 13 Ref country code: GB Payment date: 20250306 Year of fee payment: 13
2025-07-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20250305 Year of fee payment: 13
2025-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20250509 Year of fee payment: 13
2025-10-13	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240501